Printer Friendly Version View printer-friendly version
<< Back
Natera Announces First Quarter 2019 Earnings Conference Call

SAN CARLOS, Calif., May 2, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its first quarter ended March 31, 2019, after the market close on May 9, 2019. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities, and financial outlook.

Earnings Conference Call Information:

Event:

Natera's First Quarter 2019 Financial Results Conference Call

Date:

Thursday, May 9, 2019

Time:

1:30 p.m. PT (4:30 p.m. ET)

Live Dial-In:

(877) 823-0171, Domestic


(617) 500-6932, International

Conference ID:

1588676

Webcast:

https://edge.media-server.com/m6/p/w4o7a5de

Natera, Inc. Logo (PRNewsFoto/Natera, Inc.)

A webcast replay will be available at investor.natera.com.

About Natera
Natera is a global leader in cell-free DNA testing. The mission of the company is to transform the diagnosis and management of genetic diseases. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers a host of proprietary genetic testing services to inform physicians who care for pregnant women, researchers in cancer including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. Follow Natera on LinkedIn and Twitter.

Contacts
Investor Relations
Mike Brophy, CFO, Natera, 650-249-9090
Media
Andrea Sampson, Sullivan & Sampson, 714-374-6174, asampson@sullivanpr.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/natera-announces-first-quarter-2019-earnings-conference-call-300843347.html

SOURCE Natera

Footer disclaimer

Footer disclaimer

© Natera 2019. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.